QOP
SAGE

Quinn Opportunity Partners’s Sage Therapeutics SAGE Stock Holding History

Quinn Opportunity Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,888
Closed -$227K – 386
2025
Q2 		$227K Buy
+24,888
New +$183K 0.02% 293

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Quinn Opportunity Partners's SAGE Position: Q3 2025 in Review

Quinn Opportunity Partners sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 24,888 shares — an estimated $227K sold.

Quinn Opportunity Partners first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $227K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Quinn Opportunity Partners reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quinn Opportunity Partners sold 24,888 Sage Therapeutics shares in Q3 2025, an estimated $227K.
  • Quinn Opportunity Partners first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • Quinn Opportunity Partners's Sage Therapeutics position peaked at $227K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Quinn Opportunity Partners's 13F filing for Q3 2025, filed 13 Nov 2025.